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Abstract
Genotype-Driven Recruitment is a potentially powerful approach for studying human genetic
variation but presents ethical challenges. We conducted in-depth interviews with research
participants in six studies where such recruitment occurred. Nearly all responded favorably to the
acceptability of recontact for research recruitment, and genotype-driven recruitment was viewed as
a positive sign of scientific advancement. Reactions to questions about the disclosure of individual
genetic research results varied. Common themes included explaining the purpose of recontact,
informing decisions about further participation, reciprocity, “information is valuable,” and the
possibility of benefit, as well as concerns about undue distress and misunderstanding. Our findings
suggest contact about additional research may be least concerning if it involves a known element
(e.g., trusted researchers). Also, for genotype-driven recruitment, it may be appropriate to set a
lower bar for disclosure of individual results than the clinical utility threshold recommended more
generally.
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Identifying and contacting individuals about their interest in research participation must take
place within the context of well-established requirements for ethically responsible research
(National Commission, 1979). Even so, research recruitment is typically considered to
involve fewer risks than research participation. When contacted by a researcher, individuals
have several options, including not responding, expressing disinterest at the outset, or
learning more about the research and then making an informed decision about whether to
take part (Beskow et al., 2004).
However, when genetic information that is generated in one study is used as the basis for
identifying and recontacting participants about further research, concerns more commonly
associated with participation in genetic research are shifted to the recruitment phase
(Beskow et al., 2010). This kind of “recruitment by genotype” is a potentially powerful new
approach for studying the functional significance of human genetic variation (McGuire &
McGuire, 2008). Under this approach, investigators use an existing study population for
which genetic analyses have been conducted to identify individuals who possess a gene
variant of interest. Those individuals are then recontacted to invite their participation in
further research involving in-depth phenotyping to better understand the relationship
between observable traits and that particular variant (Beskow et al., 2010). Genotype-driven
recruitment eliminates the time-consuming and expensive step of screening new populations
to find subjects who have the variant of potential significance (Chulada et al., 2008). Such
recruitment could be undertaken when investigators want to recontact selected participants
in their own studies for further research (Beskow et al., 2010), in the context of biobanks
that maintain a link to identifying information (Chulada et al., 2008), and—hypothetically,
at least—by searching for individuals who have a particular gene variant across multiple
datasets stored in centralized databases, such as dbGaP (McGuire & McGuire, 2008).
Genotype-driven recruitment could increase the utility of the massive amounts of data
generated in genome-wide association studies, only a tiny fraction of which is related to the
disease or condition originally under study (McGuire & McGuire, 2008), and speed progress
toward the ultimate goal of benefitting human health.
At the same time, genotype-driven recruitment raises concerns about the use and disclosure
of genetic information as part of the offer to participate in research. There is a fundamental
tension between avoiding the disclosure of individual genetic research results that may be
unwanted and/or unsubstantiated and possibly misleading, and leaving prospective
participants uninformed about the purposes of the additional research and why they are
eligible to participate (Beskow et al., 2010).
To begin addressing this challenge, we conducted in-depth interviews with research
participants involved in studies where genotype-driven recontact occurred. We gathered
empirical data on their opinions about such contact, focusing on: (1) the acceptability of
recontact for the purposes of research recruitment and (2) whether or not genetic research
results from one study should be disclosed during the recruitment process for additional
research. These interviews were carried out collaboratively at three sites: Duke University,
the University of North Carolina at Chapel Hill, and Seattle Children’s Research Institute.
This paper reports participants’ responses to key interview questions across all sites,
including a summary of any between and/or within study variation as well as the qualitative
themes that arose in participants’ answers. Three other papers in this issue of JERHRE—one
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from each study site—delve more deeply into particular aspects of that site’s data, based
primarily on characteristics of the study population that was interviewed (Cadigan et al.,
2011; Namey & Beskow, 2011; Tabor et al., 2011).
Methods
Instrument Development
Members of the research team from across the three sites developed an interview guide
based on knowledge of the issues and literature concerning research recruitment, informed
consent, disclosure of individual genetic research results, human research protections, and
qualitative interview methodology. Because our aim was to assess and describe
interviewees’ perspectives on ethical and policy issues in the emerging area of genotype-
driven recruitment, many of our questions were framed to elicit yes/no, positive/negative, or
simple rating responses, followed by more open-ended explanations of responses. We
revised our guide through iterative rounds of comments from team members, as well as pilot
testing with three eligible participants at Duke. The guide (available upon request) shared
among the sites included questions focusing on participants’ experience and opinions
regarding research participation, informed consent, recontact for the purposes of research
recruitment, and disclosure of individual and aggregate results in the context of genotype-
driven research. Sites made minor modifications to the guide as necessary to accommodate
the characteristics of their particular study populations. The guide included a specific
definition of “individual genetic research results” to help ensure that participants were
commenting on the concept we intended (Box 1).
Data Collection
Across the three sites we interviewed a total of 78 participants who had taken part in a
diverse group of six studies where genotype-driven recontact had occurred. These original
studies differed in terms of their basic study design and study population (Table 1).
• At Duke, interviews were conducted with individuals diagnosed with epilepsy who
participated in a study of the genetics and pharmacogenetics of epilepsy
(“Epilepsy”). Following the discovery of large heterozygous deletions in some
study participants, the original researchers had carried out genotypedriven
recruitment in order to further assess the phenotypic consequences and effects on
gene expression of this deletion.
• At UNC, individuals were interviewed from two studies: One was a study of
genetic modifiers of cystic fibrosis (“CF”), involving individuals who had been
diagnosed with the condition; the second was a population-based registry of healthy
volunteers (“Biobank”). These two studies were the sources of phenotypic cases
and controls, respectively, for a genotype-driven follow-up study of cystic fibrosis
(all eligible participants had the gene variants of interest).
• At Seattle Children’s, parents were interviewed from three separate studies
involving children and in which genotype-driven recontact occurred: (1) a study
called SEARCH for Diabetes in Youth (“Diabetes”), a primary aim of which was to
develop approaches to classifying different types of diabetes; (2) the Autism
Genetic Research Exchange (“AGRE”), a repository of clinical and genetic
information designed to facilitate autism research; and (3) the Study of Autism
Genetic Exploration (“SAGE”), the goal of which was to identify genes that affect
the development of autism. The latter two studies were combined in this analysis
(and referred to as the “Autism” studies). Based on our review of the data, we
believe the shared experience of autism was more likely to influence responses to
the interview questions presented here than study-specific experiences. Combining
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these studies did not significantly change the response distributions for any
question except two; for those, we present the results separately.
We included in our interview sample participants who had and had not been recontacted as
part of the genotype-driven recruitment that occurred in the original study. A member of the
original study team initiated communication with participants, via telephone or letter, to
inform them about our interview project. We then gave interested participants additional
information and scheduled interviews with those who were eligible. Further details
concerning site-based recruitment procedures are provided elsewhere (Cadigan et al., 2011;
Namey & Beskow, in press; Tabor et al., 2011).
Interviews at each site were carried out by research team members with training and
experience conducting such interviews. Most interviews lasted between 30 and 60 minutes.
Whenever possible, interviews took place in person; when an in-person interview was not
possible, the interview was conducted by telephone. The relatively structured format of our
interview questions was intended to limit potential bias due to differences between in-person
and telephone interviews, as well as cross-site differences in how questions were asked.
With participants’ permission, interviews were audio-recorded and later professionally
transcribed for purposes of analysis. Participants provided verbal consent at the time of the
interview and were offered $40 compensation for their time.
The Institutional Review Board (IRB) at Duke University determined that the research was
exempt under 45 C.F.R. 46.101[b][2] and served as the IRB of record for the University of
North Carolina at Chapel Hill; Seattle Children’s IRB also determined this study to be
exempt.
Data Analysis
All interview transcripts were uploaded into NVivo 8 (QSR International 2008), and a
structural codebook was devised and shared among the sites. (“Structural code” refers to
question-based, rather than theme-based, codes [MacQueen et al., 1998].) Each site applied
structural codes to their own transcripts to facilitate question-based analysis across sites.
Once all structural coding was completed, the sites’ NVivo files were merged into a single
cross-site file, from which the analyses presented here were carried out. Though inter-coder
reliability is less of a concern with structural coding (given that questions and responses are
captured without regard to their thematic content), we ran code frequencies to confirm that
all questions/responses had been coded in each transcript.
Using the cross-site dataset, two coders (E.E.N and L.M.B.) working sequentially reviewed
the structural codes identified for inclusion in this analysis and performed a second round of
coding to characterize participants’ responses. We present here a description of the
approximate proportion of interviewees who gave different responses to each question and
of the variation in responses between and within the six participant groups. Due to
nonrandom sampling and small, uneven sample sizes, these proportions and variations
should not be interpreted as generalizable; rather, we are capitalizing on the structured
nature of our interview guide to facilitate clear communication about multiplex data
gathered from this particular group of interviewees. This approach also enables comparison
of responses between questions and a framework for interpreting the richer thematic data.
With regard to thematic variation, narrative segments presented here are exemplary of
frequently mentioned ideas, unless stated otherwise.
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The characteristics of our interviewees were a function of the original studies from which
they were recruited. Approximately two-thirds were female, and most were white, non-
Hispanic, and college educated (Table 2). Half had been recontacted about taking part in a
genotype-driven follow-up study (a result that follows from our purposive sampling to
interview some individuals who had been recontacted and some who had not).
Views about the Acceptability of Recontact for Genetic Research Recruitment
We asked a series of questions to ascertain interviewees’ opinions about recontact—not
necessarily genotype-driven—for the purposes of further research recruitment. Responses
were consistently positive across all of the studies to our baseline question, “Generally
speaking, if you’re in one study do you think it’s all right for researchers to contact you
about being in another study?” (Table 3). Overall, a substantial majority (> 85%) of
interviewees said “yes”. Many expressed a positive attitude toward research in general,
including themes of altruism as well as supporting the goals of research. Several recognized
recontact as an efficient way to facilitate research, particularly given that, when contacted,
one could decline further participation. Others suggested that willingness to participate in
one study was a likely indicator of willingness to participate in additional research,
particularly when the burden involved is low.
The primary concern cited with regard to recontact was privacy. Only one person across all
of the studies expressed a directly negative view, although several of those whose personal
opinion was positive anticipated that other people might have issues with privacy or be
distressed by recontact itself.
CONSENT FORM DISCLOSURES AND OPTIONS CONCERNING RECONTACT
ABOUT ADDITIONAL RESEARCH—Opinions were mixed with regard to the
importance of being informed ahead of time about the possibility of future research contact.
When asked to rate “How important would it be to you personally to know right up front
that researchers might contact you about more research in the future?” (Table 4), a majority
of Diabetes interviewees said it would be important. This was also the most common answer
among CF, Epilepsy, and Autism-AGRE interviewees, but was expressed by less than half
—reflecting the diversity of opinion within these studies. Biobank and Autism-SAGE
interviewees generally assigned less importance to being informed about the possibility of
recontact.
Many of those who said it would be important to know that recontact could occur indicated
that it was simply a good idea to give people advance notice. Some went further in
suggesting that it might factor into their decision about taking part in the initial study.
Several highlighted the potentially substantial time lag before recontact might occur as the
reason it would be important to know about the prospect early on. Some noted that
unexpected recontact could cause concerns about whether their confidentiality had been
breached.
Among interviewees who said being informed about the possibility of future research
contact was not important, some said it was not necessary because recontact itself was
acceptable. Several acknowledged that researchers may not know ahead of time that they
would later want to recontact participants.
Of the interviewees who said it would be important to be informed about such contact in
advance (n = 35), more than two-thirds said it would be important to have a choice at the
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time of initial consent about whether researchers could contact them about more research in
the future. Several interviewees noted that having a choice was important, even for
participants favorably inclined toward additional research, but especially so for those who
might want to take part in one study without being required to agree to future contact.
Interviewees who said it was not important to have a choice about recontact frequently
recognized that, if recontacted, they would still have a choice about whether to actually
participate in a subsequent study. One person linked his opinion that choice was not
important to a problem with the growing complexity of consent forms:
When you start adding in a lot of options and fine print, then it seems like
homework reading over it, and that will discourage someone like myself that tends
to be more laid back… I can see where more knowledge would be helpful, but at
the same point, too much knowledge would be a turnoff. (Biobank-C22)
POTENTIAL MODIFIERS OF VIEWS ABOUT THE ACCEPTA BILITY OF
RECONTACT FOR RESEARCH RECRUITMENT—We asked about several factors
that might modify participants’ views about the acceptability of recontact for the purposes of
research recruitment. Excluding Biobank interviewees (who had consented to participate in
a biorepository that a variety of researchers could access), responses were consistently
positive across all of the studies to our question, “How would you feel if you were contacted
about taking part in more [original condition] research, but the new study was being
conducted by researchers other than [original researchers]?” Overall, a substantial majority
(> 75%) indicated they were amenable to contact by new researchers.
Among those who indicated willingness to be contacted by new researchers (n = 49), most
said it would not matter whether the new researchers were also from the original institution.
Interviewees’ responses to both of these questions—about contact by different researchers or
by researchers from a different institution—generally reflected a positive view of research
and trust in the researchers and institutions known to them, which they often extended to
other major academic medical centers.
Finally, reactions were mixed when we asked “How would you feel if you were contacted
about taking part in more genetic research, but the new study was not about [original
condition]?” (Table 5). A majority of Epilepsy, Autism-SAGE, and Diabetes interviewees
responded positively. CF and Autism-AGRE interviewees most commonly responded
negatively, although opinions were diverse and none of the responses were expressed by a
majority. (We did not ask Biobank interviewees this question because they were recruited
from the general population, not based on having been diagnosed with a particular
condition.)
Among those who felt positively about taking part in research on other conditions, several
expressed general altruism or a desire to contribute to research on a condition affecting their
family or someone they know. Many of those who responded negatively described a
preference to focus their energies on furthering scientific knowledge about their own
condition.
ACCEPTABILITY OF GENOTYPE-DRIVEN RECONTACT FOR RESEARCH
RECRUITMENT—With regard to the acceptability of genotype-driven recontact in
particular, responses were consistently positive across all of the studies to our question
“How would you feel if the reason researchers wanted to contact you about being in a new
study was because of something they learned about your DNA in the first study?” (Table 6).
Overall, a substantial majority of interviewees (> 85%) responded favorably. Many felt such
contact would be expected or a welcome sign of scientific advancement. The opportunity to
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facilitate more research, including the perception of genetics as an important area of
research, was another frequent theme.
Interviewees frequently answered our question about the acceptability of genotype-driven
recontact by stating that they would want to know what researchers had learned. Some felt
that learning their results could influence their decision about taking part in the next study.
One person questioned the ethics of researchers not letting participants know what they had
learned:
But would that be ethical for a researcher to find something that they’re interested
in studying further pertaining to my family’s DNA and then call back and ask
questions relevant to that without letting me know, without giving me that
information? Would that be ethical research? (Autism, AGRE-S13)
No interviewee expressed a decidedly negative opinion about genotype-driven recruitment,
although some noted a few reservations—including concerns about having advance notice,
maintaining confidentiality, and the potentially distressing nature of the information.
Excluding SAGE participants (who had consented to a study where genotype-driven follow-
up was an integral component), most interviewees said it would have had little or no effect
on their decision to take part in the original study if they had known ahead of time that they
might be contacted about additional research based on something researchers had learned
about their DNA. Among those who said such knowledge would have had a big effect on
their decision, nearly all said the impact would be positive:
If they say “If you take part in this study, and we contact you as a sort of a follow-
up because we’ve detected something,” then to me that’s a positive… Because
you’re actually looking at something that could actually help benefit in some cases.
(CF-C13)
Disclosure of Research Results in the Context of Genotype-Driven Recontact
When asked, “In your opinion, when a researcher contacts people about being in a new
study, should she generally offer them their individual genetic research results from the first
study or not?” (Table 7), a large majority—ranging from approximately 60% of Epilepsy
and Diabetes interviewees to over 85% of CF and Autism interviewees—said researchers
should offer individual results. In contrast, opinions among Biobank participants were
considerably less favorable, with only about one-fourth saying results should be offered and
most expressing an uncertain or “other” response.
Among interviewees who said results should be offered in the context of genotype-driven
recruitment, many felt it would be important to explain the purpose of recontact, and some
further thought the information would be important for informing the person’s decision
about taking part in additional research. Another common reason given was the opportunity
to educate and empower patients. Although some felt that the information would be valuable
in and of itself, others seemed to assume it would convey medical or personal benefit. Some
suggested that researchers should offer results as a matter of reciprocity, i.e., receiving
information was a fair exchange for their contribution to the research. Finally, several
answered this question by stating their personal desire to receive individual results, but
explicitly noted that others might feel differently:
Some people prefer more information and other people get scared of more
information, so by leaving it up to the person to decide whether or not they want
that, I would think would be the best way to do it. I’m a curious person so I’d like
to get tons of information; other people find it alarming or whatever and may not
want it. (Diabetes-S16)
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Interviewees who said researchers should not offer people their individual genetic results
when contacting them about additional research primarily cited concerns about causing
unnecessary worry or distress. Those who did not reach a conclusion about whether
researchers should offer individual results commonly expressed uncertainty about the best
course of action, or said “it depends” on factors such as whether the information was
beneficial, and whether participants had been told in advance about such disclosure.
THE IMPORTANCE OF CLINICAL VALIDITY—When we raised the possibility that
results disclosed in the process of genotype-driven recruitment could have uncertain
validity, opinions were mixed but generally less favorable compared to our baseline question
about the disclosure of results. When asked “What if researchers find a change in a gene that
might be related to the disease they are studying, but they are not sure if it is or what it
means?” (Table 8), a majority of CF and Autism interviewees said such results should be
offered. This was also the most common response among Diabetes interviewees, although it
was expressed by less than half. In contrast, the view that such results should not be offered
was the most common response in the remaining two studies, expressed by a majority of
Biobank interviewees and many Epilepsy interviewees.
In several instances, those who said researchers should offer results even when clinical
validity was uncertain referred to the recruitment context and the importance of explaining
why they were being contacted. The beliefs that “information is good” and that people have
a right to information about themselves were other common themes, along with the potential
for taking personal responsibility to seek out other sources of information to help clarify
uncertain results.
The most common justification for why researchers should not offer uncertain results was to
avoid causing undue worry, particularly when there was no corresponding benefit. One
person noted the possibility of both undue worry and unfounded hope:
Um, boy, that’s hard, you know… I think that’s something, an ethical issue for you
guys, because you don’t want people to have false hope or false panic, and
especially if you don’t know what it means… I’m not sure they should do that.
(Autism, AGRE-S11)
Others commented that uncertain results did not constitute “information,” or that they could
cause misunderstanding or confusion.
THE IMPORTANCE OF CLINICAL UTILITY—When we asked about the disclosure of
results with uncertain utility during the process of genotype-driven recruitment (Table 9),
opinions were generally more favorable compared to the possibility of uncertain validity.
Most interviewees said researchers should offer results if they “find a change in a gene that
they are pretty sure is related to the disease they are studying, but there is no treatment or
anything different the person could do based on that information.” A majority of Biobank,
Epilepsy, and Autism interviewees expressed this view; this was also the most common
response among CF and Diabetes interviewees, although it was expressed by less than half.
Among those who said such results should be offered, the conviction that any information is
valuable was once again a common theme—sometimes described together with the belief
that individual results could provide “answers” even in the absence of clinical utility.
Interviewees also frequently mentioned the future development of medical interventions and
having the opportunity to seek those out. Some participants foresaw the possibility of more
immediate benefits, for example in terms of health-related behaviors, reproductive decision
making, or life planning. One person seemed to suggest that, in the context of genotype-
driven recruitment, researchers would need to think about their current obligations in light of
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potential future discoveries, i.e., even if the current result does not merit disclosure, the next
one might:
I think that when they find out the next result they’ll be able to say, “You didn’t tell
me this was going on in the beginning.” So a person would be deceived. (Epilepsy-
D22)
Interviewees who said researchers should not offer results that lack clinical utility cited
familiar concerns about causing undue worry with little or no possibility of benefit,
problems with understanding, and continuing uncertainty.
THE ROLE OF AGGREGATE RESULTS—Responses across all of the studies were
consistently positive with regard to the receipt of aggregate research results in the context of
genotype-driven recruitment. Overall, nearly three-fourths of interviewees said it would be
important when asked, “How important would it be to you to find out what researchers
learned about the role of genes in [original condition] in general, even if you did not get
your individual genetic research results?” (Table 10). Many felt invested in the research and
wanted to know the outcome of their contribution. Many also thought that having access to
aggregate results was an important way to stay updated about the state of scientific
knowledge. Others perceived benefit in receiving the aggregate results of genetic research,
including being able to provide information to family members who might be affected or
finding “answers” as to the cause of their medical condition. One interviewee’s comment
suggested that the provision of aggregate research results may have implications for health
care providers:
I would probably just take it and, even though I didn’t know my individual, I would
probably try … to talk with my doctor and see if we can, you know, kind of figure
out how he thought I was and … see how he thought as far as looking back at my
chart and seeing where things were… And then … when I have kids or when I have
a family like I would have that. And like if something ever did happen I’d be like,
“Hey, this was definitely me.” (Epilepsy-D21)
Discussion
Genotype-driven recruitment is an emerging approach to genomic research that poses ethical
challenges stemming from the use and possible disclosure of genetic research results as part
of the offer to participate in additional research. The concerns are exacerbated by the
uncertain nature of most genetic results: further research is needed specifically because more
must be learned to understand their meaning in terms of risk, inheritance, diagnosis,
prognosis, and treatment (Beskow et al., 2010). Genotype-driven recruitment will become an
increasingly important tool as scientists seek to better understand the function of the human
genome by recruiting individuals already known to have particular variants for in-depth
phenotyping.
To begin informing the development of policies that both protect participants and facilitate
beneficial research, we conducted in-depth interviews with participants in genomic research
where genotype-driven recontact occurred. Our interviewees were drawn from six studies
that differed in terms of basic study design and study population, thus offering the
opportunity to glean a rich array of perspectives.
Given this diversity, it is particularly striking how consistent our interviewees’ responses
were to certain questions— both within and between studies. Nearly all responded favorably
to the general acceptability of recontact for the purposes of research recruitment. These
responses were commonly accompanied by statements of altruism and a positive attitude
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toward research in general—perhaps reflective of the attitudes that might be expected
among many of those who would be candidates for genotype-driven recruitment, i.e., people
who have already agreed to participate in at least one research study. Genotype-driven
recruitment was viewed especially positively as a sign of scientific advancement and an
opportunity to take part in a promising area of research. A substantial majority of our
interviewees were amenable to contact about studies conducted by researchers other than
those who conducted the original study, perhaps again reflecting support for and trust in the
research enterprise among those who have already agreed to participate in research. Across
all studies, there was significant interest in receiving information about aggregate research
results, oftentimes for reasons related to reciprocity and staying updated on research
progress.
For several of our key questions, however, interviewees’ responses varied both within and
between studies. Although many deemed it important to be informed up front whenever
possible about the potential for future research contact and to have a choice about such
contact, others felt that having a choice about actually participating in future research was
sufficient. Similarly, many were amenable to taking part in research on other medical
conditions, but others expressed a preference to help with research on conditions affecting
them or their family and friends. Factors related to study design and study population could
help explain these findings. For example, participants in studies that are otherwise perceived
as one-time, circumscribed events (e.g., Epilepsy) may assign more importance to being
notified about the possibility for future contact as compared to studies where the ongoing
nature is an integral aspect (e.g., Biobank). Populations that are frequently recruited for
research (e.g., CF patients) may assign less importance to being notified about possible
recontact if they are already accustomed to being approached frequently. Such populations
may, however, feel less able to also contribute time and energy to research on conditions
other than their own. Study populations defined by having multiple affected family members
(e.g., Autism-AGRE) may feel similarly constrained with regard to research on other
conditions, and also rate advance notice about future research contact more highly.
Reactions to our questions about the disclosure of individual genetic research results in
particular tended to vary within and/or between studies. Common themes across all of these
questions included explaining the purpose of recontact, informing decisions about
participation in further research, reciprocity, “information is valuable,” and the possibility of
medical or personal benefit, as well as competing concerns about undue worry, distress,
misunderstanding, and confusion. Specifically with regard to our general question about
whether researchers should disclose individual results from the first study during the
recruitment process for further research, the majority of interviewees in five of the studies
said “yes”, but those in the sixth study—the Environmental Polymorphisms Registry, a
population-based biobank of healthy volunteers—had more reservations. This finding points
to a potentially significant explanatory factor, which is that patients, i.e., people who have
been diagnosed with the condition under study or parents of children with the condition,
may likely perceive the risks and benefits of receiving individual genetic results very
differently than those who have not been diagnosed with the condition (Cadigan et al., 2011;
Namey & Beskow, 2011; Tabor et al., 2011).
Responses were more mixed and less favorable to our question about disclosure of research
results that lacked clinical validity. Although many of our interviewees were receptive to
uncertain information as long as the uncertainty was clearly explained, our results suggest
that not all people diagnosed with the condition under study will find net benefit in
information that is ambiguous with regard to informing their understanding of their illness.
Likewise, healthy volunteers recruited as controls are unlikely to view unsubstantiated
information about a condition they do not have as beneficial, particularly if there is
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uncertainty about the meaning of the information for their future risk of that condition.
Overall, our interviewees seemed generally less concerned about individual results lacking
clinical utility, often based on the expectation that such results would still provide
information or answers about their illness (for people diagnosed with the condition), or the
expectation that there could still be personal utility as well as hope for future interventions
(both for people with and without the condition). Indeed, a potentially concerning facet of
our findings is the extent to which our interviewees assumed that genetic research results
would convey information serious and certain enough that they would base reproductive or
life-planning decisions on it.
As noted in the Methods section, the interpretation of all of our findings is subject to a
number of limitations. Within the time and resource constraints of our research, we were
only able to interview a small number of participants in each of the original studies and
these were not randomly sampled. In addition, most of our interviewees were white and
many were highly educated, characteristics that followed from the composition of the
original studies from which they were recruited. It is therefore critical to note that our
findings cannot be considered generalizable. We described the approximate proportions of
interviewees who gave different responses in order to facilitate the clear communication of
our data across multiple dimensions, but these proportions apply only to our particular study
sample.
Notwithstanding these limitations, our findings represent what we believe are the first data
from research participants about genotype-driven recruitment. We carried out in-depth
interviews and thus were able to gather important and nuanced insights into participants’
range of experiences and opinions, providing a strong foundation for future research.
Best Practices
Data on the opinions and preferences of research participants (as well as other stakeholder
groups) are essential for informing policy development on ethical approaches to genotype-
driven research recruitment. Although our data are provisional and subject to limitations,
they point toward several potential future practices.
First, informed consent disclosures about the possibility of recontact for the purpose of
further research recruitment is likely good research practice and may help mitigate ethical
concerns related to protecting research participants from unwelcome researcher contact
(Beskow, Namey et al., in press).
Second, our interviewees’ input suggests that contact about future research may be least
concerning if it involves a known or trusted element, e.g., the same researcher, a well-
regarded academic institution, the same medical condition.
Third, in the context of genotype-driven recruitment, it may be appropriate to set a lower
threshold for return of individual genetic research results than that typically recommended
for return of results more generally. For example, although clinical utility is commonly
considered an important factor in the decision to offer individual research results (Bookman
et al., 2006; Fabsitz et al., 2010; NBAC, 1999), this is a threshold that may rarely be met in
the context of genotype-driven recruitment. Findings from our interviews suggest that
setting a lower bar for disclosure may be important for avoiding evasion when explaining to
prospective participants the purposes of the additional research and why they are eligible,
and for promoting informed decision making about further research participation. These
reasons for offering results are fundamentally different than those suggested by studies of
participant preferences in other contexts, where individual genetic research results were
desired because of anticipated personal or health-related benefit (Beskow & Smolek, 2009;
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Kaufman et al., 2008; Meulenkamp et al., 2010; Murphy et al., 2008; Ormond et al., 2009;
Wendler & Emanuel, 2002).
Finally, our results suggest that factors related to study design and study population may
have an important impact on prospective participants’ reactions to genotype-driven
recruitment and the disclosure of individual genetic research results. Thus, there is unlikely
to be a one-size-fitsall approach to genotype-driven recruitment, but rather several
approaches that are acceptable when tailored based on careful consideration of contextual
factors and informed by empirical evidence whenever possible.
Research Agenda
A strength of our study was the diverse group of original studies from which we recruited
interviewees, allowing us to identify a range of perspectives on this emerging topic. In
companion papers (Cadigan et al., 2011; Namey & Beskow, 2011; Tabor et al., 2011), we
offer more detailed examinations of these different views. However, our sample size was too
small for further meaningful stratified analyses (e.g., by demographic factors), which would
be a fruitful area for future research.
Another strength of our study was that we obtained detailed responses from participants in
genomic research to a series of questions about the return of individual genetic results.
Participants’ (or hypothetical participants’) basic interest in receiving such results has been
well documented, but more nuanced exploration of their understanding and preferences—
including issues of validity and utility—has been limited. Further research is warranted on
this important topic.
The role of aggregate research results also deserves more attention. The provision of
aggregate results could be a pivotal step in the process of genotype-driven recruitment, and
also serve an important function in terms of satisfying participants’ desire to stay updated,
find answers as to potential causes of their condition, and to receive something in exchange
for their participation (Beskow, Burke et al., in press).
More generally, further research on genotype-driven recruitment should build on our
findings and be implemented in studies ideally involving larger sample sizes and the
opportunity to gather data from participants prospectively, i.e., before and during the process
of genotype-driven recruitment, rather than after it has occurred. It will be vital to assess
how participants react to the receipt of genetic information (see, e.g., Green et al., 2009) and
what they do with that information. Data from other stakeholders, including researchers,
physicians, and IRB chairs (Beskow, Namey et al., in press) is critical to the development of
balanced approaches to genotype-driven recruitment.
Educational Implications
When planning genomic research, it is important that research teams and IRBs be aware of
the possible future desire to conduct genotype-driven recruitment and of the ethical
dilemmas it entails. In particular, they should think about the range of opinions,
assumptions, and expectations— as well as potential misunderstandings—that may be held
by prospective participants. Whenever possible, it would be beneficial to take steps during
the initial study design phase to educate themselves about their particular study populations
and to tailor their plans and consent disclosures accordingly. They must also be prepared to
communicate clearly with participants about the state of genomic science in their area of
research: what is known and not known about the role of genomic factors and the next steps
in the research process.
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Box 1. Interview guide definition of “individual genetic research results”
Sometimes when people are contacted about taking part in another study, they are given
some individual genetic results from the first study. For example, they might be told what
researchers had learned about their genes or DNA. Sometimes they are not given any
individual information back.
People think of a lot of different things when they hear “genetic results.” For the next
several questions, we’re going to be talking about something quite specific that I will call
“individual genetic research results.” Let me explain [READ THE FOLLOWING
ALOUD]:
Researchers doing a genetic study are usually trying to find out whether there is
a link between a genetic trait and the medical condition they are studying. By
looking at the DNA from everyone in the study, researchers are sometimes able
find such a trait. Some people in the study have that particular trait and some
people don’t. Also, researchers sometimes know something about that genetic
trait and what it might mean—but often they are not sure what it means or if it is
even related to the medical condition until they do more studies.
So, when I say, “individual genetic research results,” I mean information about whether
or not you have the genetic trait that researchers identified in their study. Does that make
sense to you? Do you have any questions about this definition?
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Title of original study Genetics and Pharmacogenetics of Epilepsy (“Epilepsy”)
Subjects 975 adults with epilepsy
Recontact for additional research
described in consent form?
Yes
Options offered in consent form
concerning recontact?
No
Consent form disclosures about
results
Participants will not receive research results, but will be offered “incidental findings”
Consent form options about results None
Method of recontact Letter, then phone call
Individual results provided during
recontact?
No
UNIVERSITY OF NORTH CAROLINA-CHAPEL HILL
Title of original study Gene Modifiers in Cystic
Fibrosis (“CF”)
Environmental Polymorphisms Registry (“Biobank”)
Subjects 1,306 adults and children
with CF
15,000 adult “healthy volunteers”
Recontact for additional research
described in consent form?
No Yes
Options offered in consent form
concerning recontact?
No No
Consent form disclosures about
results
Participants may receive
results of “potential clinical
consequence”
Participants will not receive results; may or may not receive results in
follow-up studies
Consent form options about results Participants can opt to
receive results of “potential
clinical consequence”
None
Method of recontact In person, in the clinic Letter
Individual results provided during
recontact?
No, but told they have one
of two genetic variants that
may affect severity of CF
No, but told they have one of two genetic variants under study and
there is no known relationship between these variants and any disease
in people who do not have CF
SEATTLE CHILDREN’S
Title of original study Autism Genetic Resource
Exchange (“AGRE”)*
Study of Autism Genetics
Exploration (“SAGE”)*
SEARCH for Diabetes in Youth
(“Diabetes”)
Subjects 1,163 families with >1 child
with autism
1,000 children (with autism
or suspected ASD) and their
parents
3,474 children with diabetes
Recontact for additional research
described in consent form?
No Yes Yes
Options offered in consent form
concerning recontact?
Yes No, because recontact was
part of the study design
Yes
Consent form disclosures about
results
Participants will not receive
results
Parents will be told if child
has gene variation being
studied. No other results
given
Results may be given to diabetes
provider
Consent form options about results Option for return of specific
test results (Fragile X
None Participants can opt for their provider
to receive results

















Method of recontact Phone call Letter, then phone call Letter
Individual results provided during
recontact?
No Yes, told that CNV was




SAGE and AGRE were combined in this analysis as the “Autism” studies; see Methods section for more details.
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TABLE 2
Interview Participant Characteristics (n = 78).
n %*
Age: Mean = 43; range = 21–67
Education
    High school 13 17
    Associate’s degree 3 4
    Some college 6 8
    Bachelor’s degree 37 47
    Graduate degree 18 23
Sex
    Female 50 64
    Male 28 36
Race
    White 67 86
    Black 8 10
    Other 3 4
    Hispanic 2 3
Original study
    Gene Modifiers in Cystic Fibrosis (CF) 9 12
    Environmental Polymorphisms Registry (Milbank) 15 19
    Genetics and Pharmacogenetics of Epilepsy (Epilepsy) 29 37
    Autism Genetic Resource Exchange (AGRE) 13 17
    Study of Autism Genetics Exploration (SAGE) 5 6
    SEARCH for Diabetes in Youth (Diabetes) 7 9
Recontacted about follow-up study 39 50
*
May not sum to 100% due to missing data.
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TABLE 3
“Generally speaking, if you’re in one study do you think it’s all right for researchers to contact you about
being in another study?”
Response Theme Examples
Yes Positive attitude toward
research, altruism
• Because I think that it will help others, by getting more information as you go … you
want to find out one answer, then you keep working to find more answers. (Epilepsy-
D03)
• I guess I figure anything that will help… figure out what gene it’s on or figure out, you
know, like what gives kids a predisposition to get it or whatever, I’m happy to do
whatever I can to figure it out. (Autism, AGRE-S02)
Efficient way to facilitate
research
• Yeah, I think it’s all right for them to contact you because … there’s not a large pool of
people with those characteristics… [T]hey already got the names and contact numbers
… it’s easier to do that than go out to the community and recruit new people and try to
sift through those names and stuff. So just reasonable to assume that’s how that would
be done. (Autism, AGRE-S06)
• If you don’t contact people … that have the problem, and ask or at least offer to do
studies, then you can’t advance anywhere with it. So the worst they can do is say no. I
don’t see any problem with that. (Epilepsy-D14)
Inclination to participate • I think that if I was able to agree to do one, to be open to that … I don’t see a reason
why I should have a concern to do another one. (Epilepsy-D15)
Minimal burden • Well, I mean, it’s just really not a whole lot to it, so I don’t see where it’s that big a deal
… whether you’re in two or three or one. I mean it’s not that hard to do. (Epilepsy-D12)
No Privacy • Well, I don’t know. I mean, I just thought that was a one-time deal… So, that’s really
the only reason why I did it. I didn’t think it was going to be a continuous string of them
(Epilepsy-D09).
• I could see how maybe some people would feel like their privacy might have been
violated… It wouldn’t bother me, but it may bother others. I could see how other people
might not be happy about that. (Diabetes-S08)
Distress • I could see how somebody could perceive it—you know, be concerned or could raise
alarms like “You know I was contacted because something was wrong.” (Biobank-C07)
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TABLE 4
“How important would it be to you personally to know right up front that researchers might contact you about
more research in the future?”
Response Theme Examples
Important Advance notice • When you go and you participate in a study … unless it’s made explicitly
clear, you kind of assume that it’s … open and closes when you leave… It’d
be nice to have a heads up that you could be contacted again in the future.
(Biobank-C07)
Inform participation decision • I think that’s kind of a “duh” question, frankly (laughs). I mean … maybe I’m
wrong, but most people want to know as much as they could about what their
participation might look like. (Autism, AGRE-S11)
• That would be good to know. It would because it would … make you kind of
think “Do I really want to be in this study if it’s gonna have some impact on
my future?” (Biobank-C12)
Time lag before recontact • At least it plants maybe a seed in your mind that you know you’re signing up
for something longer term than just a 15-minute blood draw. (Biobank-C08)
• Even if I get a letter and it’s two, three years later, at least I know. I like to be
a little bit prepared. (Epilepsy-D25)
Confidentiality • I mean, you would just like to know that if you are going to do something one
time, that you know your information would be … kept confidential and
secure, and if you were contacted again when you were told that it was a one-
time thing, you would think that maybe your information was compromised.
(Biobank-C20)
Not important Recontact itself is okay • It wouldn’t be important to me, because… I think that’s an okay thing to do.
If somebody contacted me for a second study, I wouldn’t feel like I had been
misled somehow, because I didn’t know that they might do that. (Autism,
AGRE-S01)
Researchers may not anticipate
recontact
• If that is the intent, fine. I don’t think that would make a difference to sign up
for the first study. If that’s not known ahead of time, then you can’t tell the
person. (Biobank-C19)
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TABLE 5
“How would you feel if you were contacted about taking part in more genetic research, but the new study was






• Well I probably got the gene for breast cancer ’cause my mom died of that, my grandma, my aunt.
So I probably got that gene too. So if they can cause me not to have breast cancer, that’d be good.
(Epilepsy-D13)
• Autism is not the only thing that needs fixed. There’s other things that are just as important, like
heart disease or … a predisposition to cancer, diabetes, any of those things. I mean, if it was for
something like Huntington’s disease, I probably wouldn’t see any possible reason why I should
participate since nobody in my family has ever had it. But if it was something that affected our
family, personally… (Autism, AGRE-S01)
Negative Focus on own
condition
• I think I would stick to the epilepsy. The epilepsy is what’s involving me, it’s what I’m looking to
know more about. I would stay with the epilepsy. (Epilepsy-D29)
• I want to help somebody that’s got the same problem I got, you know. (CF-C16)
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TABLE 6
“How would you feel if the reason researchers wanted to contact you about being in a new study was because
of something they learned about your DNA in the first study?”
Response Theme Examples
Positive Sign of scientific advancement • I think that’d be great … you would know that the other study worked. (CF-
C16)
• That’s fine. I mean, DNA, that sounds like it could be moving, progressing
somewhere. Yeah, that would be good. (Epilepsy-D06)
• I would be very happy about that. I mean I would say, “Yay, I’m helping
make a difference finding something.” (Autism, SAGE-S23)
Facilitate more research • It’s always good to learn new things about genetics and DNA. So I think it’d
be great to learn new stuff and do more research based on what’s been
learned. That’s the whole point of doing research. (CF-C17)
• Oh, I’m fine with that … if they found, let’s say, we have a predisposition to
autism on gene chromosome number 8 or whatever, I’d be fine like if they
took all the people they thought that had this … and did another study. I think




Would want to know what
researchers had learned
• If there was something they learned about my DNA, and they want to look
into it further, I would understand the value of that. I would have no problems
with that. I mean for obvious reasons I might be a little anxious if there was
something that they found out. I would want to know what it is. (Biobank-
C11)
• That would be fine, although I’d wanna know probably what they see that
makes them want to look at my DNA. (Epilepsy-D05)
Inform participation decision • I’d be willing if it’s something that was in my DNA the first time or genetics,
it’s good for me to be informed of that and that’s why I would be willing to




Advance notice • Being up front in the beginning is the key to it. If I agree to something ahead
of time, I know they’re doing it. If I assume that I’m an anonymous donor,
and then later on I find out I’m not, then I feel betrayed I guess is the right
term for it. (Biobank-C10)
Confidentiality • I guess it would depend on if they were a part of the study that they had
learned that from. Like if they were just kind of a third party researcher and
they learned it through like friends or like seeing the results or whatever it
would be a little bit more worrisome for me. (Diabetes-S19)
Nature of the information • I think I would feel totally fine with that—unless like the topics of the study or
whatever they found was something alarming. (Biobank-C04)
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TABLE 7
“when a researcher contacts people about being in a new study, should she generally offer them their
individual genetic research results from the first study or not?”
Response Theme Examples
Should offer Explain purpose of recontact • I think people have a right to know, if they’re going to participate in a new
study, why. (Epilepsy-D04)
Inform participation decision • I think they should. I think that makes a person more wanting to do the
research if it’s something they found. Otherwise it puts them in the dark, “Why
am I doing this again?” (Autism, AGRE-S07)
Educate/empower patients • I think any time you have an opportunity to educate a person about CF,
particularly if they have it, you should try to do so. I just think that we, in order
to be independent and for survival … I like to know what’s going on with my
body and, you know, what my results are. (CF-C01)
Medical/personal benefit • I just think it’s important for people to know. I mean for me … if there’s gonna
be a new drug to market or something that’s gonna be beneficial, to me that’s
something that I’d want to know. (CF-C13)
• It’s interesting and it would help to kind of clarify things a little bit for me. I
mean, I don’t know why I have epilepsy. I can’t really tie it to anything in
particular, so for me it would be great to be able to go, “Oh … it’s all so clear
now.” (Epilepsy-D19)
Reciprocity • Yeah, ’cause that’s their blood. They have a right to know what’s going on. If I
sat down and … willingly gave somebody some of my blood for a test, I think
I should get it back. I should know the grade of my test since I took it.
(Epilepsy-D09)
Should not offer Undue worry, distress • The science is too new I think… I don’t know that it might—it might cause
more worry than necessary. (Biobank-C08)
• It depends on whether it’s bad or could be interpreted as bad. It’s hard to say.
You have to be careful about handing out information to people, especially
genetic stuff ’cause these days it’s the hot topic and “Oh they know this about
my DNA,” and “What does it mean? What does it mean?” I think it’s probably
best to not say. (Epilepsy-D16)
Uncertain Unsure • I don’t know. I’m not really sure on that one. I guess you could go either way
because … if everyone wants to know how their results turned out, you know,
that could be costly and not really … time effective and all that. (Diabetes-
S19)
Other It depends • I would say—well, only if it falls into that “I really know for sure this matters
in your life” category. I think only if there’s concrete knowledge that you can
work with should you tell people. Because this is like you know false positives
on tests. All it does is freak people out for no reason. And people waste their
lives and all their energy and effort chasing something that’s not real and is
stupid. (Biobank-C09)
• It depends on whether or not the participant agrees to that up front and whether
the researcher discloses that up front. (Biobank-C20)
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TABLE 8
“what if researchers find a change in a gene that might be related to the disease they are studying, but they are
not sure if it is or what it means?”
Response Theme Examples
Should offer Explain purpose of recontact • Yes, I think, people would want to know. You know, “Why are you being a
vampire and taking my blood again?” (laughs) I just don’t want to give away
blood willy nilly. (Epilepsy-D04)
Information is valuable • Well, again it’s—I think yeah. The participant would want to know everything
that they could get their hands on. (Biobank-C15)
• It’s all still good information. (Autism, SAGE-S22)
Right to know • As long as the researcher is clear and tells them they are not sure what it
means, I think people should have the right to know that. (Autism, AGRE-S18)
Personal responsibility • Because if I have an abnormality in a gene, I’m going to remember that, I’m
going to write it down. And then as I do my end research, I can see where
someone else is working on that gene or whatever, will catch my attention. No
one is going to monitor it any better than I am. (Autism, AGRE-S10)
Should not offer Undue worry, distress • I think that would do more harm than good… If you can’t be 100% sure, then
don’t tell them because that’s just gonna give them worry. That’s just gonna
make them think “Oh my God. Am I—what’s gonna happen to me? What’s
gonna happen to my kids?” (Biobank-C12)
• No. No. That’s a perfect example of when not to, because you don’t know.
And you give somebody some information, they’re just going to go with it and
assume the worst. (Epilepsy-D16)
Not “information” • Those are not real knowledge. It’s not truth yet. It’s a speculation. It’s a
hypothesis. It’s a guess. And I don’t think that’s fair to put that in somebody’s
head. (Biobank-C09)
Misunderstanding, confusion • It puts more of a question mark in the person’s head as whether or not they’re
all right or something’s going to get worse. And it makes them more confused.
(Epilepsy-D03)
• If it’s unclear to a researcher what it might mean, then I’m not sure if I can
make any head or tail of it either, so I may not necessarily need to know that.
(Autism, AGRE-S13)
Uncertain Unsure • That one can be kind of a mixed bag. It can kind of go between people that
might take the information just for the sake of having all the information
necessary in case it becomes relevant, but then there’s some people that might
… nitpick and be overly worried that they have this gene and freak out about
it. (CF-C17)
Other It depends • I think you have to look at the whole situation. How bad is their situation?
How far gone is their disease? You have to weigh everything in … and then
the individual themselves. That could be tough to answer. That could really be
tough. (Epilepsy-D14)
Inform physician • The patient’s doctor should know. The patient should let the researchers know
who their doctor is. And maybe the doctor should tell the patients, if the
doctors know what to do. But let the doctors make that call. (Epilepsy-D28)
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TABLE 9
“what if researchers find a change in a gene that they are pretty sure is related to the disease they are studying,
but there is no treatment or anything different the person could do based on that information?”
Response Theme Examples
Should offer Information is valuable • I would still want to know. There may be a cure for epilepsy, there may not.
There may be a treatment, there may not. But I want to know everything I
can about epilepsy, good, bad and ugly. I just want to know everything ’bout
it. (Epilepsy-D29)
Answers • Yeah it would be good to have that information simply because it helps you
understand why you’re experiencing what you’re experiencing. Whether
there is a treatment or not. Certainly answer a lot of the questions. (Epilepsy-
D07)
Future interventions • You might as well know because there might be a treatment, and then if you
hear on the news, “Oh, you know this study done two years ago found this.
Well, the researchers have recently identified a drug that’s able to handle
that.” Somebody’s going to call up their doctor. (Biobank-C18)
• Even if you can’t get a treatment now there is always a hope for treatment
down in the future. (Autism, AGRE-S09)
Immediate benefit, personal
utility
• Even if there wasn’t a treatment maybe there’s some things you could do to
lessen the severity or, you know, if you exercised more or something like
that, that it somehow would at least help the situation. (Autism, SAGE-S21)
• Let’s say they found the chromosome that caused autism, but even if there
was nothing that they could do prenatally to fix it, it might be nice to know
“Hey, here’s your percentages of having another kid with autism.” I still
think it would be good for people to know to make informed decisions.
(Autism, AGRE-S02)
• Let’s say you discover a gene that’s going to make me die in five years. If
you tell me that I have this gene, I can plan my life, you know, I can do my
estate planning or whatever. I would live my life differently knowing that I
was going to die sooner. (Autism, SAGE-S25)
Should not offer Undue worry, distress • That’s something they really don’t need to know if there is no cure for it. It
would worry somebody. (Epilepsy-D24)
Misunderstanding, confusion • I mean if there’s no way to treat it … the average person is not gonna be able
to understand “Oh. Something’s wrong with this gene.” I mean they are not
going to know what that really means. (CF-C03)
Continuing uncertainty • If there’s nothing you can do about it, and it’s not a—it’d be one thing if that
gene is 100% correlated to a condition… [but] there are a lot of genes that
are correlated to a lot of things that just never happen in a lot of people.
(Biobank-C10)
Uncertain/Other It depends • Well it kind of depends on the situation the person is in. If they have high
hope (laughs) they probably shouldn’t know at all. Or it’s just hard to
answer. (Epilepsy-D01)













Beskow et al. Page 27
TABLE 10
“How important would it be to you to find out what researchers learned about the role of genes in [original
condition] in general, even if you did not get your individual genetic research results?”
Response Theme Examples
Important Outcome of contribution • I would like that. That would be very interesting. It would be nice, if I participate in a
study and a paper is written, to get the paper even though I wouldn’t understand
probably the abstract, but I could look through it and see that I feel that I’ve made a
contribution. Whether mine actually helped or not I can at least think it did. (Biobank-
C10)
• It’s important to know what they’re doing, why they’re doing it. They’re not just
coming around and giving you a test and saying, “Okay, filled out, see you later.” No,
you’d like to know that your time and effort is getting some kind of results. (Epilepsy-
D06)
• I mean I’m curious, “Has this helped anybody? Have they found any great answers?
Are they coming up with new methods?” (Diabetes-S08)
Stay updated • It’s important to me. I find the research interesting and obviously we have a personal
interest in it, but even if the information wasn’t something that was going to be directly
applicable to my family or something, I think it’s helpful to know. I want to know as
much as I can. (Autism, SAGE-S24)
Provide information to
family
• Even if I don’t know for a fact it’s for me, it would allow me to know that a possibility
is there that it could be hereditary. And that it could still be something I could look for
in my kids. (Epilepsy-D29)
Answers • It would be very important. I mean I think it would make me understand exactly how
my daughter got it. (Diabetes-S03)
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